Overview

Romiplostim earns its place when oral thrombopoietin-receptor agonists stop working, making acquired resistance and treatment sequencing the defining theme of its use. NPLATE supplies romiplostim 250 μg as a subcutaneous injection in single-use vials, an alternative route for immune thrombocytopenia patients who have lost response to oral agents. This article explains why a peptide-mimetic TPO agonist can re-establish platelet control after failure of small-molecule options. Recognising the resistance scenario helps buyers keep the right format available for refractory cohorts.

How It Works

Romiplostim is a Fc-peptide fusion protein that mimics endogenous thrombopoietin, binding and activating the TPO receptor on megakaryocytes to boost platelet production. Because it is a peptide agonist rather than a small-molecule TPO-RA, it engages the receptor through a different molecular interaction. When a patient develops inadequate response to an oral TPO-RA such as eltrombopag, switching to romiplostim can restore efficacy through this distinct mechanism and route, a key consideration in sequential ITP management.

Indications

Romiplostim is indicated for chronic immune thrombocytopenia in adults and children who have had an insufficient response to other therapies including corticosteroids, immunoglobulins, or splenectomy. It is also used in refractory ITP after oral agent failure. The 250 μg vial supports weekly subcutaneous dosing titrated to a stable platelet target. Buyers should plan cold-chain and sterile-handling capacity for the injectable format.

Dosage & Administration

Romiplostim is given as a weekly subcutaneous injection starting at 1 mg/kg, with stepwise adjustment by 1 mg/kg to a maximum of 10 mg/kg to reach and maintain a platelet count of at least 50 per microlitre. The 250 μg vial is reconstituted and dosed per patient weight. Treatment is continuous and monitored; doses are not fixed per pack, so inventory tracks individualised weekly demand.

Storage & Sourcing

Store romiplostim refrigerated at 2 to 8°C, protected from light; do not freeze. As a biologic injectable, it demands cold-chain transport and sterile handling, raising sourcing complexity versus oral tablets. B2B buyers need a licensed supplier, GMP evidence, and batch documentation. Confirm remaining shelf life and plan around weekly dosing schedules, since the peptide degrades if storage conditions lapse.

FAQ

Q: Why switch to romiplostim after oral TPO-RA failure? A: Romiplostim is a peptide TPO agonist with a different molecular interaction and route, so it can restore platelet response when small-molecule oral agents lose effect.

Q: How is romiplostim dosed given variable patient weight? A: It is dosed weekly by body weight in mg/kg and titrated to a platelet target, so inventory follows individualised, not fixed, consumption.

Q: What storage conditions does the injectable require? A: Refrigeration at 2 to 8°C with light protection and intact cold-chain transit; freezing or temperature excursions invalidate the product.